For Immediate Release

Oricura Therapeutics Advances Hearing Loss Treatment Candidate ORC-13661 to Phase 1 Multiple Ascending Dose Trial

SEATTLE, Wash. (August 30, 2018) – ORICULA THERAPEUTICS, LLC, a biotech company introducing medications to preserve hearing and balance, announced that the company has successfully completed the single dose (SAD) study of ORC-13661 safety in 32 normal human volunteers. ORC-13661 is the company’s experimental treatment aimed at preventing aminoglycoside-dependent hearing loss. In September 2018 Oricura plans to begin the second Phase 1 trial of ORC-13661, to study multiple ascending doses (MAD) in normal human volunteers.

"We are very pleased with the excellent safety and pharmacology results seen in our initial SAD Phase 1 study of ORC-13661 in healthy volunteers. ORC-13661 showed linear dose proportionality, high estimated bioavailability, half-life consistent with once daily dosing, and very low variability between subjects," said Vince Groppi, Ph.D., pharmacologist and Board Member of Oricura. "We believe this compound has the potential to benefit the lives of patients with bacterial infections that need to be treated."

ORC-13661 is a novel, first in class therapeutic agent that inhibits aminoglycoside-induced hearing loss by a novel mechanism of action. This unique mechanism of action has the potential to expand the use of aminoglycosides to treat life-threatening infections.

About Oricura Therapeutics
Founded in 2013, privately held Oricura Therapeutics, LLC, headquartered in Seattle, Wash., is one of the first biotech companies introducing medications to preserve hearing and balance from the damaging effects of medications and aging. Oricura is commercializing research conducted at the University of Washington and the Fred Hutchinson Cancer Research Center and holds an exclusive license to the resulting intellectual property. Oricura received major funding through the National Institute of Deafness and Communication Disorders, the National Institute of Allergy and Infectious Disease and the Washington State Life Science Discovery Fund. This uniquely positions Oricura to introduce the first FDA-approved medication designed specifically to prevent hearing loss for patients undergoing aminoglycoside antibiotic treatment and expand the worldwide use of these inexpensive yet effective antibiotics to treat life-threatening bacterial infections. Oricura’s first product has received FDA Initial New Drug (IND) approval to proceed with human trials. For more information, visit ORICULARX.COM.

Media Contact:  Cheryl Isen, Media Relations
Cheryl@IsenandCo.com or 425.233.9032